Combination therapy for acute lymphoblastic leukemia

(Journal of Clinical Investigation) In this issue of JCI Insight, Charles Mulligan of St. Jude Children's Research Hospital and colleagues show that a combination approach using tyrosine kinase inhibitors and an inhibitor of focal adhesion kinase was much more effective in preclinical models of BCR-ABL1+ B-progenitor acute lymphoblastic leukemia.